Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
Common airborne contaminants introduced during needle draws including Staphylococcus epidermidis and Pseudomonas aeruginosa can multiply to unsafe levels at room temperature
10.1016/j.cbpa.2018.01.007 568 Stumme-DiersM
It's prescribed for patients with confirmed vitamin B12 deficiency, especially those who cannot absorb B12 properly from food or oral supplements
GI events (nausea, vomiting, diarrhea) were the dominant safety signal and occurred at rates higher than reported for Phase 2 retatrutide and higher than for comparable dual or mono-agonist trials
The examples table shows how different vial sizes behave at your selected concentration
US$ 24.88
US$ 27.31
US$ 23.83
US$ 29.09
US$ 20.22
US$ 21.40
US$ 25.07